At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b, Randomized, Double-blind (Sponsor Open), Placebo Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf 04447943, Co-administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
In Brief
A Phase 1 clinical trial evaluating PDE9i and placebo for PDE9i for Phase 1 Sickle Cell. Completed, enrolled 30 participants across 23 sites in 5 countries.
Detailed Summary
This study is being conducted to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of an investigational drug, PF-04447943, in subjects with stable sickle cell disease with and without co-administration with hydroxyurea. This study will also aid in selecting the doses for future studies and evaluation of substances in the blood which may help access the effectiveness of the drug.
Study Details
Timeline
Interventions
oral dose, every 12 hours for 28 days
oral dose, every 12 hours for 28 days
oral dose, every 12 hours for 28 days
oral dose, every 12 hours for 28 days